TABLE OF CONTENTS
1 INTRODUCTION 49
1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET 49
1.4 CURRENCY AND PRICING 51
1.5 LIMITATIONS 51
1.6 MARKETS COVERED 51
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 DBMR TRIPOD DATA VALIDATION MODEL 58
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
2.6 MULTIVARIATE MODELLING 62
2.7 MARKET END USER COVERAGE GRID 63
2.8 TEST TYPE LIFELINE CURVE 64
2.9 DBMR MARKET POSITION GRID 65
2.10 VENDOR SHARE ANALYSIS 66
2.11 SECONDARY SOURCES 67
2.12 ASSUMPTIONS 67
3 EXECUTIVE SUMMARY 68
4 PREMIUM INSIGHTS 70
4.1 PESTEL ANALYSIS 73
4.2 PORTER'S 5 FORCES 74
5 EPIDEMIOLOGY 75
6 INDUSTRIAL INSIGHTS 76
7 REGULATORY FRAMEWORK 77
8 MARKET OVERVIEW 79
8.1 DRIVERS 81
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 81
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 81
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 82
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 82
8.2 RESTRAINTS 83
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 83
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 83
8.3 OPPORTUNITIES 84
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 84
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 84
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 85
8.4 CHALLENGES 85
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 85
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 86
9 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 87
9.1 OVERVIEW 88
9.2 IMAGING 91
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 92
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 93
9.2.1.2 ANALOG MAMMOGRAPHY 93
9.2.1.3 3D BREAST TOMOSYNTHESIS 93
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 93
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 93
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 93
9.2.1.7 OTHERS 93
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 93
9.2.2.1 OPTICAL IMAGING 94
9.2.2.2 BREAST ULTRASOUND 94
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 94
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 94
9.2.2.5 BREAST THERMOGRAPHY 95
9.2.3 BIOPSY 95
9.2.3.1 SURGICAL BIOPSY 96
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 96
9.2.3.3 CORE NEEDLE BIOPSY 96
9.2.3.4 IMAGE-GUIDED BIOPSY 96
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 97
9.2.4 GENOMIC TEST 97
9.2.4.1 MOLECULAR TESTING 98
9.2.4.1.1 PD-L1 99
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 99
9.2.4.1.3 NTRK GENE FUSIONS 99
9.2.4.1.4 PI3KCA GENE MUTATION 99
9.2.4.2 MAMMAPRINT 99
9.2.4.3 ONCOTYPE DX 99
9.2.4.4 OTHERS 99
9.3 BLOOD TEST 100
9.4 OTHERS 101
10 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 102
10.1 OVERVIEW 103
10.2 INVASIVE DUCTAL CARCINOMA 106
10.3 DUCTAL CARCINOMA IN SITU 106
10.4 INFLAMMATORY BREAST CANCER 107
10.5 METASTATIC BREAST CANCER 108
11 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER 109
11.1 OVERVIEW 110
11.2 HOSPITALS 112
11.3 DIAGNOSTICS CENTERS 113
11.4 CLINICS 114
11.5 RESEARCH & ACADEMIC INSTITUTES 114
11.6 OTHERS 115
12 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 117
12.1 OVERVIEW 118
12.2 DIRECT TENDER 121
12.3 RETAIL SALES 121
12.4 OTHERS 122
13 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY REGION 123
13.1 OVERVIEW 124
13.2 NORTH AMERICA 129
13.2.1 U.S. 137
13.2.2 CANADA 143
13.2.3 MEXICO 149
13.3 EUROPE 155
13.3.1 GERMANY 164
13.3.2 FRANCE 170
13.3.3 RUSSIA 176
13.3.4 ITALY 182
13.3.5 U.K. 188
13.3.6 SPAIN 194
13.3.7 TURKEY 200
13.3.8 NETHERLANDS 206
13.3.9 BELGIUM 212
13.3.10 SWITZERLAND 218
13.3.11 IRELAND 224
13.3.12 REST OF EUROPE 230
13.4 ASIA-PACIFIC 231
13.4.1 CHINA 240
13.4.2 INDIA 246
13.4.3 JAPAN 252
13.4.4 INDONESIA 258
13.4.5 PHILIPPINES 264
13.4.6 THAILAND 270
13.4.7 AUSTRALIA 276
13.4.8 MALAYSIA 282
13.4.9 SOUTH KOREA 288
13.4.10 SINGAPORE 294
13.4.11 REST OF ASIA-PACIFIC 300
13.5 SOUTH AMERICA 301
13.5.1 BRAZIL 309
13.5.2 ARGENTINA 315
13.5.3 REST OF SOUTH AMERICA 321
13.6 MIDDLE EAST AND AFRICA 322
13.6.1 EGYPT 331
13.6.2 SOUTH AFRICA 337
13.6.3 ISRAEL 343
13.6.4 SAUDI ARABIA 349
13.6.5 UAE 355
13.6.6 REST OF MIDDLE EAST AND AFRICA 361
14 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 362
14.1 COMPANY SHARE ANALYSIS: GLOBAL 362
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 363
14.3 COMPANY SHARE ANALYSIS: EUROPE 364
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 365
15 SWOT ANALYSIS 366
16 COMPANY PROFILE 367
16.1 HOLOGIC, INC. 367
16.1.1 COMPANY SNAPSHOT 367
16.1.2 REVENUE ANALYSIS 367
16.1.3 COMPANY SHARE ANALYSIS 368
16.1.4 PRODUCT PORTFOLIO 368
16.1.5 RECENT DEVELOPMENTS 369
16.2 SIEMENS HEALTHCARE GMBH 370
16.2.1 COMPANY SNAPSHOT 370
16.2.2 REVENUE ANALYSIS 371
16.2.3 COMPANY SHARE ANALYSIS 371
16.2.4 PRODUCT PORTFOLIO 372
16.2.5 RECENT DEVELOPMENTS 372
16.3 F. HOFFMANN- LA ROCHE LTD 373
16.3.1 COMPANY SNAPSHOT 373
16.3.2 REVENUE ANALYSIS 373
16.3.3 COMPANY SHARE ANALYSIS 374
16.3.4 PRODUCT PORTFOLIO 374
16.3.5 RECENT DEVELOPMENTS 375
16.4 KONINKLIJKE PHILIPS N.V. 376
16.4.1 COMPANY SNAPSHOT 376
16.4.2 REVENUE ANALYSIS 376
16.4.3 COMPANY SHARE ANALYSIS 377
16.4.4 PRODUCT PORTFOLIO 377
16.4.5 RECENT DEVELOPMENTS 378
16.5 ABBOTT 379
16.5.1 COMPANY SNAPSHOT 379
16.5.2 REVENUE ANALYSIS 379
16.5.3 COMPANY SHARE ANALYSIS 380
16.5.4 PRODUCT PORTFOLIO 380
16.5.5 RECENT DEVELOPMENTS 380
16.6 ABACUS ALS 381
16.6.1 COMPANY SNAPSHOT 381
16.6.2 PRODUCT PORTFOLIO 381
16.6.3 RECENT DEVELOPMENTS 381
16.7 BD 382
16.7.1 COMPANY SNAPSHOT 382
16.7.2 REVENUE ANALYSIS 382
16.7.3 COMPANY SHARE ANALYSIS 383
16.7.4 PRODUCT PORTFOLIO 383
16.7.5 RECENT DEVELOPMENTS 383
16.8 BIOCEPT, INC. 384
16.8.1 COMPANY SNAPSHOT 384
16.8.2 REVENUE ANALYSIS 384
16.8.3 PRODUCT PORTFOLIO 385
16.8.4 RECENT DEVELOPMENTS 385
16.9 BIOMRIEUX 386
16.9.1 COMPANY SNAPSHOT 386
16.9.2 REVENUE ANALYSIS 386
16.9.3 PRODUCT PORTFOLIO 387
16.9.4 RECENT DEVELOPMENTS 387
16.10 BIO-RAD LABORATORIES, INC. 388
16.10.1 COMPANY SNAPSHOT 388
16.10.2 REVENUE ANALYSIS 388
16.10.3 PRODUCT PORTFOLIO 389
16.10.4 RECENT DEVELOPMENT 389
16.11 CEPHEID 390
16.11.1 COMPANY SNAPSHOT 390
16.11.2 REVENUE ANALYSIS 390
16.11.3 PRODUCT PORTFOLIO 391
16.11.4 RECENT DEVELOPMENT 391
16.12 EXACT SCIENCES CORPORATION 392
16.12.1 COMPANY SNAPSHOT 392
16.12.2 REVENUE ANALYSIS 392
16.12.3 COMPANY SHARE ANALYSIS 393
16.12.4 PRODUCT PORTFOLIO 393
16.12.5 RECENT DEVELOPMENTS 394
16.13 FUJIFILM CORPORATION 395
16.13.1 COMPANY SNAPSHOT 395
16.13.2 REVENUE ANALYSIS 395
16.13.3 PRODUCT PORTFOLIO 396
16.13.4 RECENT DEVELOPMENT 396
16.14 GENERAL ELECTRIC 397
16.14.1 COMPANY SNAPSHOT 397
16.14.2 REVENUE ANALYSIS 397
16.14.3 PRODUCT PORTFOLIO 398
16.14.4 RECENT DEVELOPMENTS 398
16.15 ILLUMINA, INC. 399
16.15.1 COMPANY SNAPSHOT 399
16.15.2 REVENUE ANALYSIS 399
16.15.3 PRODUCT PORTFOLIO 400
16.15.4 RECENT DEVELOPMENTS 400
16.16 MYRIAD GENETICS, INC. 401
16.16.1 COMPANY SNAPSHOT 401
16.16.2 REVENUE ANALYSIS 401
16.16.3 PRODUCT PORTFOLIO 402
16.16.4 RECENT DEVELOPMENT 402
16.17 NANOSTRING. 403
16.17.1 COMPANY SNAPSHOT 403
16.17.2 REVENUE ANALYSIS 403
16.17.3 PRODUCT PORTFOLIO 404
16.17.4 RECENT DEVELOPMENT 404
16.17.5 RECENT DEVELOPMENT 404
16.18 ONCOSTEM. 405
16.18.1 COMPANY SNAPSHOT 405
16.18.2 PRODUCT PORTFOLIO 405
16.18.3 RECENT DEVELOPMENT 405
16.19 PROVISTA DIAGNOSTICS. 406
16.19.1 COMPANY SNAPSHOT 406
16.19.2 PRODUCT PORTFOLIO 406
16.19.3 RECENT DEVELOPMENT 406
16.20 THERMO FISHER SCIENTIFIC INC. 407
16.20.1 COMPANY SNAPSHOT 407
16.20.2 REVENUE ANALYSIS 407
16.20.3 PRODUCT PORTFOLIO 408
16.20.4 RECENT DEVELOPMENT 408
17 QUESTIONNAIRE 409
18 RELATED REPORTS 412

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.